Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 27;139(4):492–501. doi: 10.1182/blood.2020010439

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by The American Society of Hematology

This article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 3. — PFS by MRD status (10⁻⁵) among all patients in MAIA and ALCYONE and in the pooled daratumumab-based combination groups vs control groups. Kaplan-Meier estimates of PFS based on MRD negativity in the ITT populations. MRD negativity was assessed at a threshold of 1 tumor cell per 10⁵ white blood cells. (A) The red line shows patients who achieved MRD negativity at any time since randomization; the blue line shows patients who were MRD positive. (B) Red lines show regimens containing daratumumab (D-Rd and D-VMP); blue lines show standard of care regimens (Rd and VMP). A total of 5 patients who achieved a best response of VGPR were also MRD negative (all from the D-VMP arm of ALCYONE). Dara, daratumumab; VGPR, very good partial response.